Hemolytic-Uremic Syndrome clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
open to eligible people ages 18 years and up
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Torrance, California and other locations
Our lead scientists for Hemolytic-Uremic Syndrome research studies include Sarah Tomassetti.
Last updated: